Claims for Patent: 6,420,421

Summary for Patent: 6,420,421

Title:	Pharmaceutical composition and of using the same
Abstract:	A pharmaceutical composition is provided for systemically treating a living mammal or avian. The composition preferably comprises an alkyl-dimethyl-benzyl-ammonium chloride, an alkyl-dimethyl-ethylbenzyl-ammonium chloride, and an organotin compound in a vehicle suitable for systemically treating a living mammal or avian of viral, bacterial, fungal infections and diseases, including HIV in humans.
Inventor(s):	Phillips; Mark W. (Coconut Creek, FL)
Assignee:	Zetetic Research, Inc. (Coconut Creek, FL)
Application Number:	09/757,339
Patent Claims:	1. A pharmaceutical composition for systemically treating a living mammal or avian comprising a first quaternary ammonium compound, a second quaternary ammonium compound and an organometallic compound in a vehicle effective for systemically treating a living mammal or avian, said vehicle being selected from the group consisting of ringers solution, lactated ringers solution, dextrose solution, NaCl solution, and other pharmaceutically acceptable diluents except sterile water effective for systemic administration of said compounds to a living mammal or avian. 2. A composition according to claim 1, wherein said first quaternary ammonium compound is an alkyl-dimethyl-benzyl-ammonium chloride, said second quaternary ammonium compound is an alkyl-dimethyl-ethylbenzyl-ammonium chloride, and said organometallic compound is an organotin compound. 3. A composition according to claim 1, wherein said first quaternary ammonium compound is n-alkyl(60%C.sub.14, 30%C.sub.16, 5%C.sub.12, 5%C.sub.18)-dimethyl-benzyl-ammonium chloride, said second quaternary ammonium compound is n-alkyl(68%C.sub.12, 32%C.sub.14)-dimethyl-ethylbenzyl-ammonium chloride, and said organometallic compound is bis(tri-n-butyltin)oxide or a water-soluble or water-dispersable ester thereof. 4. A composition according to claim 1, said composition being about 0.5 to 0.00005 weight percent said first quaternary ammonium compound, about 0.5 to 0.00005 weight percent said second quaternary ammonium compound, and about 0.02 to 0.000002 weight percent said organometallic compound. 5. A composition according to claim 3, said composition being about 0.5 to 0.00005 weight percent said first quaternary ammonium compound, about 0.5 to 0.00005 weight percent said second quaternary ammonium compound, and about 0.02 to 0.000002 weight percent said organometallic compound. 6. A composition according to claim 3, said composition being about 0.005 weight percent said first quaternary ammonium compound, about 0.005 weight percent said second quaternary ammonium compound, and about 0.0002 weight percent said organometallic compound. 7. A composition according to claim 3, wherein the weight ratio of said first quaternary ammonium compound to said second quaternary ammonium compound is from 10:1 to 1:10 and the weight ratio of said first quaternary ammonium compound to said organometallic compound is from 500:2 to 50:20. 8. A composition according to claim 1, wherein said vehicle is selected from the group consisting of ringers solution and lactated ringers solution. 9. A composition according to claim 1, wherein said vehicle is a 5% dextrose solution. 10. A composition according to claim 1, wherein said vehicle is a NaCl solution. 11. A composition according to claim 1, wherein said vehicle is effective for intravenous administration to a living mammal or avian. 12. A composition according to claim 1, wherein said vehicle is effective for subcutaneous administration to a living mammal or avian. 13. A composition according to claim 1, wherein said vehicle is effective for intra-nasal administration to a living mammal or avian. 14. A composition according to claim 1, wherein said vehicle is effective for intra-muscular administration to a living mammal or avian. 15. A composition according to claim 1, wherein said vehicle is effective for administration to a living mammal or avian through nebulization. 16. A composition according to claim 1, wherein said first quaternary ammonium compound is alkyl-dimethyl-benzyl-ammonium chloride. 17. A composition according to claim 1, wherein said second quaternary ammonium compound is alkyl-dimethyl-ethylbenzyl-ammonium chloride. 18. A composition according to claim 1, wherein said organometallic compound is an organotin compound. 19. A composition according to claim 1, wherein the weight ratio of said first quaternary ammonium compound to said second quaternary ammonium compound is from 10:1 to 1:10. 20. A composition according to claim 1, wherein the weight ratio of said first quaternary ammonium compound to said organometallic compound is from 500:2 to 50:20. 21. A composition according to claim 1, wherein said organometallic compound is a organotin compound. 22. A composition according to claim 1, wherein said composition consists essentially of said first quaternary ammonium compound, said second quaternary ammonium compound, and said organometallic compound. 23. A composition according to claim 22, wherein said first quaternary ammonium compound is an alkyl-dimethyl-benzyl-ammonium chloride, said second quaternary ammonium compound is an alkyl-dimethyl-ethylbenzyl-ammonium chloride, and said organometallic compound is an organotin compound.

Details for Patent 6,420,421

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2020-01-10